DealHorizon - the faster, easier way to create and share business plans

Long a subject of debate in the telecom world, femtocells are poised to become a household word, as some of the barriers to widespread deployment will fall away with the end of 2009 and the beginning of 2010.

Hadar Ron, managing partner at Israel HealthCare Ventures, whose firm last raised a $140 million second fund in 2006, and Yael Margolin, chief executive of Gamida Cell Ltd., provided answers to a few questions on the state of the stem cell market.

A flurry of acquisitions and the possible opening of an initial public-offering window are giving health-care VCs reason for optimism about exiting prospects in 2010. With the economy improving, acquirers are striking while valuations remain reasonable. Recently, Johnson & Johnson agreed to buy Acclarent Inc., Cubist Pharmaceuticals Inc. bought Calixa Therapeutics Inc., and Celgene Corp. said it would acquire Gloucester Pharmaceuticals Inc., for example. Rising stock prices are also stoking public-investor interest in new offerings, some observers contend. Expecting an IPO window next year, a few companies have filed to go public recently, including AVEO Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc. and Aldagen Inc. Yet investors continue to see M&A as their primary exit option, even for companies that do go public. And many suspect that the recent spate of merger deals will continue into 2010.

A daily roundup of venture capital news and opinion.

Embattled health care banking services company Canopy Financial Inc. wants to sell its assets to health care technology company TriZetto Group Inc. for $6.1 million in cash.

A roundup of venture capital news.

Appolicious Inc. has raised $1.5 million from Apex Partners, after having raised a seed round of $500,000 from the same firm in May.

A roundup of venture capital-related news from around the Web.

Entrepreneurs need to understand the market in which they are pitching, and the pressures on that market, according to a consultant to CEOs of early-stage companies.

A roundup of the latest venture-capital news and analysis across the Web.

Despite rumblings about renewed interest in public offerings, medical-device company Acclarent, once an IPO candidate itself, opted for the safer arms of an acquirer rather than wait for a window that may not widen.

A roundup of the latest venture-capital news and analysis across the Web.

A roundup of the latest venture-capital news and analysis across the Web.

Holiday "e-cards" have become popular in recent years, first as a way to cut back on paper clutter but increasingly as an outlet for ever-more creative messages as this firms shows.

Holiday "e-cards" have become popular in recent years, first as a way to cut back on paper clutter but increasingly as an outlet for ever-more creative messages as this firms shows.

Venture capital investors in China are souring on U.S. exchanges and turning instead to domestic markets and Hong Kong for their exits.

A roundup of the latest venture-capital news and analysis across the Web.

Investors say new mobile devices will emerge that will change the way consumers buy, sell and consume content, while major tech companies and wireless carriers will battle for control of this content.

Most venture capital firms shy away from the Midwest manufacturing and automotive industries, instead favoring high-technology regions like Silicon Valley. Not RPM Ventures.

A roundup of the latest venture-capital news and analysis across the Web.